Antiviral agents for infectious mononucleosis

Review objective: To assess the effectiveness of antiviral therapy in improving outcomes for patients with Infectious Mononucleosis (IM). IM is a clinical syndrome that is usually associated with EBV infection. Although generally not considered a serious illness, IM can lead to significant loss of time from school or work due to profound fatigue (1). Also, it can rarely lead to potentially life-threatening complications such as splenic rupture, encephalitis and severe upper airway obstruction (2). As such, there is great interest in developing regimens for treating IM with antiviral agents. To our knowledge, there are no professional society guidelines currently for the management of IM. This indicates a lack of evidence regarding treatments and the importance of further evidence-based research.

Award Date

29 September 2013

Award Value

€107,745

Principal Investigator

Dr Muireann De Paor

Host Institution

Royal College of Surgeons in Ireland

Scheme

Cochrane Training Fellowships